{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T12:26:21Z","timestamp":1791721581369,"version":"4.3.4"},"reference-count":30,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T00:00:00Z","timestamp":1576195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["W1101\u2010B12"],"award-info":[{"award-number":["W1101\u2010B12"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Prostate cancer (PCa) is one of the most frequently diagnosed tumors in men. In general, therapies for localized PCa are curative. However, treatment of advanced PCa is considered palliative since development of therapy resistance occurs rapidly. It has been shown that tumor\u2010initiating cells are likely involved in therapy resistance. They are not eliminated by conventional therapies and thereby lead to tumor progression and relapse. The aim of this study was to evaluate the effects of the known stem cell inhibitor salinomycin on this critical subpopulation of cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Expression of the cell surface markers CD24 and CD44 was assessed by immunofluorescence and fluorescence\u2010activated cell sorting. Colony formation efficiency and classification of colony types with varying tumor\u2010initiating potential (holoclones, meroclones, and paraclones) were analyzed in an automated way by the newly developed CATCH\u2010colonies software in the absence or presence of salinomycin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Automated high\u2010resolution colony formation analysis consistently identified the various colony types in a broad range of PCa cell lines. Serial clonogenic assays confirmed that holoclones show the highest colony formation potential and maintain their tumor\u2010initiating capacity over multiple rounds. Furthermore, holoclones showed high expression of CD44, while CD24 was not expressed in these clones, thus representing the well\u2010described tumor\u2010initiating CD24<jats:sup>\u2212<\/jats:sup>\/CD44<jats:sup>high<\/jats:sup> population. Salinomycin decreased the CD24<jats:sup>\u2212<\/jats:sup>\/CD44<jats:sup>high<\/jats:sup> population in both docetaxel\u2010sensitive PC3 and docetaxel\u2010resistant (DR) PC3\u2010DR. Moreover, treatment of PC3, DU145, PC3\u2010DR, and DU145\u2010DR with salinomycin led to a significant reduction in the colony formation potential by targeting the colonies with high tumor\u2010initiating potential.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Taken together, we demonstrated that salinomycin specifically targets the tumor\u2010initiating cell population in docetaxel\u2010sensitive and docetaxel\u2010resistant PCa cells and may represent a potential therapeutic approach for the treatment of advanced PCa.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.23940","type":"journal-article","created":{"date-parts":[[2019,12,13]],"date-time":"2019-12-13T16:48:52Z","timestamp":1576255732000},"page":"267-273","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The stem cell inhibitor salinomycin decreases colony formation potential and tumor\u2010initiating population in docetaxel\u2010sensitive and docetaxel\u2010resistant prostate cancer cells"],"prefix":"10.1002","volume":"80","author":[{"given":"Martina","family":"Gruber","sequence":"first","affiliation":[{"name":"Department of Urology, Division of Experimental Urology Medical University of Innsbruck  Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Handle","sequence":"additional","affiliation":[{"name":"Department of Urology, Division of Experimental Urology Medical University of Innsbruck  Innsbruck Austria"},{"name":"Department of Cellular and Molecular Medicine Molecular Endocrinology Laboratory, KU Leuven  Leuven Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-6153","authenticated-orcid":false,"given":"Zoran","family":"Culig","sequence":"additional","affiliation":[{"name":"Department of Urology, Division of Experimental Urology Medical University of Innsbruck  Innsbruck Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,12,13]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05744.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/35102167"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2011.07.008"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.09.003"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.8.2302"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0931"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.01.015"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5878"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.4271"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-319"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089834"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317695035"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0530291100"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2012.08.011"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0775"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000541"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2011.10.010"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945012802429615"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2014.2529"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2016.00115"},{"key":"e_1_2_8_22_1","first-page":"4101653","article-title":"Salinomycin exerts anticancer effects on PC\u20103 cells and PC\u20103\u2010derived cancer stem cells in vitro and in vivo","volume":"2017","author":"Zhang Y","year":"2017","journal-title":"BioMed Res Int"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13410"},{"issue":"2","key":"e_1_2_8_24_1","first-page":"877","article-title":"Salinomycin induces apoptosis and differentiation in human acute promyelocytic leukemia cells","volume":"40","author":"Zhao Y","year":"2018","journal-title":"Oncol Rep"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.06.034"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.515"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141919"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.10.042"},{"issue":"2","key":"e_1_2_8_29_1","first-page":"2495","article-title":"Salinomycin may inhibit the cancer stem\u2010like populations with increased chemoradioresistance that nasopharyngeal cancer tumorspheres contain","volume":"16","author":"Zhang G","year":"2018","journal-title":"Oncol Lett"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/950658"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb2697"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.23940","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.23940","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pros.23940","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.23940","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T21:40:41Z","timestamp":1694122841000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.23940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,13]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["10.1002\/pros.23940"],"URL":"https:\/\/doi.org\/10.1002\/pros.23940","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,13]]},"assertion":[{"value":"2019-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}